‘Biologics Fill / Finish Service Providers, 2019-2030’ (By Roots Analysis) Knowpia

To order this detailed 480+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/biologics-fill--finish-services-market-2019-2030/256.html

Key Inclusions

§ A detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target immune checkpoints, their respective mechanisms of action (inhibitory or stimulatory), type of therapeutic modality used (monoclonal antibody, antibody fragment, small molecule and others), route of administration (intravenous, subcutaneous, oral and others), target disease indication, target therapeutic area and type of therapy (monotherapy, combination therapy and both).

§ A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, type of target, target indication(s), target therapeutic area(s), enrolled patients population and regional distribution.

§ Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis of the number of pipeline products), featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and recent collaborations. In addition, each profile includes an informed future outlook.

§ An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects, in the period between 2016 and 2019 (till November), including analysis based on important parameters, such as year of grant award, amount awarded, administration institute center, funding institute center, support period, type of grant application, purpose of grant award, grant mechanism, popular target immune checkpoints, responsible study section, focus area, prominent program officers, and type of recipient organizations. It also features a detailed analysis based on the types of target immune checkpoints and therapeutic areas, along with a multivariate grant attractiveness analysis based on parameters, such as grant amount, support period, type of grant application and number of disease indications under investigation.

§ An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements (specific to affiliated technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, manufacturing agreements, mergers and acquisitions, manufacturing and service agreements, and other relevant types of deals.

§ An insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for next generation immune checkpoint therapy development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of grants and number of publications [B] a five-dimensional spider-web analysis, highlighting the most popular immune checkpoint targets.

§ An analysis of the big biopharma players engaged in this domain, featuring a heat map based on parameters, such as number of therapies under development, target disease indications, partnership activity and target portfolio.

§ Informed estimates of the existing market size and the future opportunity for contract fill / finish services for biologics, over the next decade. Based on multiple parameters, such as biopharmaceutical contract services market size, share of fill / finish services and their likely outsourcing profile, we have provided informed estimates on the evolution of the market for the period 2019-2030.

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

§ Types of Primary Packaging Containers

§ Ampoules

§ Cartridges

§ Syringes

§ Vials

§ Types of Biologics

§ Peptides / proteins

§ Antibodies

§ Vaccines

§ Cell therapies

§ Gene therapies

§ Viral products

§ Oligonucleotides

§ Others

§ Company Size

§ Small-sized

§ Mid-sized

§ Large / very large

§ Scale of Operation

§ Preclinical

§ Clinical

§ Commercial

§ Key Therapeutic Areas

§ Cancer

§ Infectious diseases

§ Autoimmune diseases

§ Cardiovascular diseases

§ Other indications

§ Key Geographical Regions

§ North America (US, Canada)

§ Europe (UK, France, Germany, Italy, Spain and rest of the Europe)

§ Asia-Pacific (Japan, China, South Korea, India and Australia)

The report features inputs from a number of eminent industry stakeholders, according to whom, “Currently, majority of biologics are being filled in vials, however, the scenario is likely to change in the future due to the growing demand and preference for self-administration devices.” The report features detailed transcripts of discussions held with the following experts:

§ Ales Sima, Business Development Manager, oncomed manufacturing

§ Gregor Kawaletz, Chief Commercial Officer, IDT Biologika

§ Jos Vergeest, International Business Developer, HALIX

§ Purushottam Singnurkar, Research Director and Head of Formulation Development, Syngene International

To request sample pages, please visit this - https://www.rootsanalysis.com/reports/256/request-sample.html

Key Questions Answered

§ Who are the leading industry players engaged in the contract fill / finish services market for biologics?

§ Which are the prominent packaging formats used for biologics?

§ Where are the players setting up new facilities or adding infrastructure across the globe?

§ Which partnership models are commonly adopted by stakeholders in this industry?

§ What is the current fill / finish supply?

§ What is the demand for contract fill / finish services for biologics?